Novartis told to pay 75% of defendants’ costs in Exelon case

08-06-2015

Novartis told to pay 75% of defendants’ costs in Exelon case

360b / Shutterstock.com

The English High Court has ordered Novartis to pay 75% of the defendants’ legal costs in a patent infringement case against Focus Pharmaceuticals, Actavis and Teva.


English High Court, Novartis, Exelon, costs, Focus Pharmaceuticals, Actavis, Teva; rivastigmine

LSIPR